Correlation of Inter-Locus Polyglutamine Toxicity with CAG•CTG Triplet Repeat Expandability and Flanking Genomic DNA GC Content by Nestor, Colm E. & Monckton, Darren G.
Correlation of Inter-Locus Polyglutamine Toxicity with
CAGNCTG Triplet Repeat Expandability and Flanking
Genomic DNA GC Content
Colm E. Nestor
1,2,3*, Darren G. Monckton
1
1Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Breakthrough
Breast Cancer Research Unit, University of Edinburgh, Edinburgh, United Kingdom, 3Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh,
United Kingdom
Abstract
Dynamic expansions of toxic polyglutamine (polyQ)-encoding CAG repeats in ubiquitously expressed, but otherwise
unrelated, genes cause a number of late-onset progressive neurodegenerative disorders, including Huntington disease and
the spinocerebellar ataxias. As polyQ toxicity in these disorders increases with repeat length, the intergenerational
expansion of unstable CAG repeats leads to anticipation, an earlier age-at-onset in successive generations. Crucially, disease
associated alleles are also somatically unstable and continue to expand throughout the lifetime of the individual.
Interestingly, the inherited polyQ length mediating a specific age-at-onset of symptoms varies markedly between disorders.
It is widely assumed that these inter-locus differences in polyQ toxicity are mediated by protein context effects. Previously,
we demonstrated that the tendency of expanded CAGNCTG repeats to undergo further intergenerational expansion (their
‘expandability’) also differs between disorders and these effects are strongly correlated with the GC content of the genomic
flanking DNA. Here we show that the inter-locus toxicity of the expanded polyQ tracts of these disorders also correlates with
both the expandability of the underlying CAG repeat and the GC content of the genomic DNA flanking sequences. Inter-
locus polyQ toxicity does not correlate with properties of the mRNA or protein sequences, with polyQ location within the
gene or protein, or steady state transcript levels in the brain. These data suggest that the observed inter-locus differences in
polyQ toxicity are not mediated solely by protein context effects, but that genomic context is also important, an effect that
may be mediated by modifying the rate at which somatic expansion of the DNA delivers proteins to their cytotoxic state.
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Introduction
A growing number of inherited human diseases have been
associated with DNA tandem repeat instability, trinucleotide
repeats of the motif CAGNCTG comprising the largest class of such
repetitive elements [1]. Expanded CAGNCTG repeat disorders can
be further categorised into two principle classes depending upon
the location of the array within the associated gene. The first class,
which includes myotonic dystrophy type 1 (dystrophia myotonica 1,
DM1), is defined by a repeat expansion in a non-coding region of
the gene. The second class is defined by a polyglutamine (polyQ)-
encoding CAG repeat. The unstable CAG polyQ repeat disorders
include Huntington disease (HD), spinal and bulbar muscular
atrophy, X-linked (SMAX1, also known as SBMA/Kennedy
disease), dentatorubral-pallidoluysian atrophy (DRPLA), Ma-
chado-Joseph disease (MJD, also known as SCA3), and the
spinocerebellar ataxias, 1 (SCA1), 2 (SCA2), 7 (SCA7) and 17
(SCA17). Each of these polyQ disorders is a late-onset neurode-
generative disease associated with the loss of specific neuronal
populations [2]. The repeat tracts in the associated gene in all
these disorders are typically small (,5–30 repeats), polymorphic
and stably transmitted within the general population. Disease
associated alleles in patients have expanded beyond this range and
typically contain at least 35 repeats. Although non-coding alleles,
such as in the DM1 associated gene, may expand to thousands of
repeats, inherited polyQ-coding alleles rarely exceed 100 repeats
in humans [2].
Expanded trinucleotide repeat instability is described as a
‘dynamic mutation’, as the frequency and magnitude of length
changes vary as the repeat number changes [3]. These dynamic
mutations are strongly biased towards expansion in a repeat-length
dependent manner, giving rise to increases of allele length from
one generation to the next [4,5,6]. Moreover, expansions may
occur in multiples of repeat units in each step. This contrasts with
the instability observed at normal-length polymorphic microsatel-
lites, at which one repeat unit expansions and contractions are
equally favoured, resulting in a stable distribution of microsatellite
lengths over time [7].
Significantly, at expanded trinucleotide repeats toxicity increases
with length, longer repeat tracts resulting in greater levels of cell
death and dysfunction in affected tissues, and a more severe
phenotype. Thus, intergenerational increases in expanded triplet
repeat length are consistent with ‘anticipation’, a clinical charac-
teristic commonto these disorders, whereby an earlier age of disease
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generations [1]. In addition to intergenerational expansion, high
levels of age-dependent, expansion-biased, tissue-specific somatic
mosaicism are also observed [8,9]. For example, analysis of post-
mortem brain tissue from HD patients has revealed high levels of
somatic mosaicism and very large expansions in the striatum, the
primaryaffected tissueinthisdisorder[10].Similarly,DM1patients
have significantly longer average allele lengths in muscle compared
with blood [11,12,13], emphasising the relationship between tissue-
specific somatic expansion and pathogenesis. Thus, it has been
proposed that whilst intergenerational repeat expansion accounts
for the phenomenon of anticipation, somatic expansion is likely to
be a major contributing factor in disease progression and the tissue-
specificity of symptoms [1].
The precise mechanism(s) underlying the dynamic mutation of
CAGNCTG repeats remains unknown. Indeed, transgenic mouse
studies have variously implicated a range of DNA repair genes
including Msh2 [14], Msh3 [15], Pms2 [16], Ogg1 [17], Dnmt1
[18], DNA ligase 1 [19] and Xpa [20]. Surprisingly however, a
genome wide analysis did not find a correlation between the
steady state DNA repair gene transcript levels and the tissue
specificity of repeat instability [21]. Nonetheless, it is clear that
two components of the DNA mismatch repair machinery, Msh2
and Msh3, are absolutely required to generate both germ line
and somatic mutations in mice [14,15,22,23] suggesting one
major pathway, possibly mediated by inappropriate DNA
mismatch repair [1]. In addition to obvious trans-acting factors
involved in governing expanded repeat behaviour such as the
mismatch repair system, sex of the transmitting parent and tissue
type [1], numerous lines of evidence suggest a major role for cis-
acting factors in CAGNCTG instability. Expanded CAGNCTG
instability is locus-specific, not genome-wide indicating that
factors local to the repeat influence its mutability. The most
obvious factors are those internal to the array such as number of
repeats and sequence purity [24]. However, a growing body of
evidence from murine models of CAGNCTG instability also
support the involvement of cis-elements in the DNA sequences
flanking the repeat unit [25,26,27,28,29,30]. Likewise, we
previously revealed that the intergenerational expandability (a
length-normalised measure of propensity toward repeat expan-
sion) of the human disease associated expanded CAGNCTG
repeat loci differ significantly from one another, confirming a
role for additional cis-acting modifiers of repeat stability flanking
the repeat [31]. Moreover, we showed that inter-locus variation
in expanded CAGNCTG repeat dynamics is strongly correlated
with the GC content of the genomic flanking DNA, with the
most expandable loci having the highest flanking GC contents
[31].
As all the dynamic repeat disorders that possess an expanded
polyQ tract are dominant, display a similar inverse relationship
between polyQ length and age-at-onset, and lead to progressive
neuronal degeneration [2], it appears not unreasonable to suggest
that expanded polyQ tracts are inherently toxic and that some
aspects of polyQ toxicity may be conserved between disorders.
This idea is strengthened by the finding that insertion of a long
polyQ encoding tract into the mouse Hprt gene can reproduce
features of the associated human disorders including a late onset
neurological phenotype and neuronal intranuclear inclusions [32].
Similarly, the expression of a long polyQ tract with only 10
flanking amino acids can cause a neurodegenerative phenotype in
Drosophila [33]. Moreover, protein mis-folding, the formation of
polyQ containing aggregates and transcriptional misregulation in
affected tissues are molecular abnormalities clearly shared by all
the disorders [34].
Despite shared components of the pathogenic pathway, and
although all expanded polyQ disorders show a similar inverse
relationship between polyQ number and age-at-onset of symp-
toms, the absolute number of polyQ repeats associated with a
given age-at-onset of symptoms varies considerably between the
disorders [2]. For example, whereas an age-at-onset of 40 years in
MJD typically requires the individual to inherit more than 70
repeats, an inherited allele length of less than 45 repeats will have a
similar age-at-onset in SCA2 [2]. These inter-locus differences in
polyQ toxicity are widely assumed to be a consequence of the
different protein contexts in which each polyQ tract is found in its
host protein [34,35,36,37,38], resulting in markedly different
toxicity thresholds between disorders. Such protein context effects
could be mediated by amino acid sequences flanking each polyQ
tract modifying the cytotoxic potential of the polyQ tract (e.g. by
modifying aggregation dynamics), or by effects on the normal
function of the protein.
As the size of the native expanded-polyQ containing proteins
varies greatly (41 kDa–347 kDa), their primary sequences are not
similar, and the position of the tract relative to the translation start
site differs, the polyQ tracts clearly do have very different protein
contexts. Indeed, there is ample evidence that changing the
flanking amino acid sequence of an expanded polyQ tract can
change its pathogenic potential. For instance, studies in yeast
showed that altering the flanking sequence of an expanded HD
HTT exon 1 fragment, by the simple addition of a FLAG-tag,
caused a previously non-toxic fragment of HTT exon 1 to induce
characteristic length-dependent polyQ toxicity [39]. Similarly,
deletion or replacement of the Josephin domain of expanded
polyQ-containing ATXN3 significantly reduced the propensity of
the protein to form aggregates [40], as did deletion or replacement
of the AXH domain of the ATXN1 protein [35]. Other findings
suggest that polyQ protein context could mediate cytotoxicity by
affecting the ability of the ubiquitin-proteasome system to target
and clear the cell of toxic expanded proteins and aggregates
[41,42]. Similarly, polyQ toxicity can be modified by the
phosphorylation status of flanking amino acids. Strikingly,
replacement of a single serine phosphorylation site with an alanine
residue in an ATXN1 transgene with a long polyQ tract
dramatically reduces toxicity [43], while conversely replacement
of the same serine with a phospho-mimetic aspartic acid residue
renders a wild type ATXN1 transgene with a short polyQ tract
cytotoxic [44]. Indeed, there is mounting evidence that some of
the pathological effects of polyQ expansions can be mediated
through a gain of normal protein activity [45]. Thus, protein
context can have a major effect on polyQ toxicity and it seems
very likely that some of the observed difference in inter-locus
polyQ toxicity will be attributable to protein context effects.
However, other than to say that certain protein contexts are more
or less toxic, taken together the known protein context effects offer
no quantifiable rationalisation of the observed inter-locus
differences in polyQ toxicity.
It is our primary hypothesis that ongoing somatic expansion
contributes toward disease progression in the repeat expansion
disorders [1]. Under such a scenario the age-at-onset of symptoms
in an individual can be rationalised as the product of a sufficiently
high proportion of cells having acquired a sufficiently large repeat
tract to mediate tissue dysfunction. Therefore, any major modifier
of the dynamics of somatic expansion should also modify the age-
at-onset of symptoms. Consequently, for a group of disorders, such
as the polyQ disorders, that share some aspects of a common
downstream pathogenic pathway, differences in the underlying
somatic stability of the expanded repeat should result in differences
in the relationship between the number of repeats inherited and
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expandability delivers polyQ proteins to their cytotoxic state
would be a critical factor in expanded polyQ-disease pathogenesis,
and might contribute toward the observed inter-locus differences
in polyQ toxicity. Here we tested this hypothesis, by quantifying
the relationship between inter-locus polyQ toxicity, CAGNCTG
repeat expandability and flanking DNA GC content.
Results
Defining inter-locus polyQ toxicity
In order to investigate the factors mediating differences in
polyQ toxicity, we sought to develop a robust quantitative measure
of inter-locus polyQ toxicity. Previously, Gusella and MacDonald
analysed published studies to collate measured repeat length versus
age-at-onset data from large numbers of patients with the polyQ
disorders [2]. The data set comprises measured polyQ length and
age-at-onset for over 2,400 individuals with at least 100 patients
for each disorder. Although patients may acquire very large
somatic expansions in the affected brain region [10], levels of
somatic mosaicism in the peripheral tissues used for genotyping
are generally very low [8,46,47] such that we can assume that the
measured allele length represents the inherited repeat length.
Using these data, we carried out a detailed statistical analysis of the
nature of the relationship between inherited repeat number and
age-at-onset both within and between the seven dynamic DNA
polyQ disorders. Firstly, we determined that the majority of
individuals with these disorders initially develop symptoms in adult
life, with a modal age-at-onset of 32 years. Juvenile cases, with an
age at onset under 20 years, are relatively rare, but develop an
extreme phenotype that is very similar between the disorders and
in which the well defined regional specificity of the adult onset
neuropathology is lost [48,49,50,51]. Moreover, because of this
extreme differential phenotype and the paucity of juvenile onset
data for most of these disorders, cases with an age-at-onset under
20 years of age were excluded from the analyses. Testing a range
of curve estimation regression models, an exponential decay
function was found to best describe the relationship between age-
at-onset and repeat number for all disorders. Subsequently, we
used the parameters derived from the regression analysis for each
disorder to calculate the inherited repeat number predicted to
result in an age-at-onset of 32 years, the modal age-at-onset
(Figure 1A, Table 1, and Figure S1). We propose that the repeat
numbers thus obtained, represent a robust quantitative measure of
the relative inter-locus polyQ toxicity confirming SCA2 and SCA7
as the most toxic, and DRPLA and MJD as the least toxic, polyQ
expansions. Although some earlier, small-scale studies reported a
simple linear relationship between age-at-onset and repeat length
it is widely recognised that the relationship is best modelled by an
exponential function [2,52,53,54]. In any case, modelling the
relationship between age-at-onset and repeat length using a simple
linear function generated similar values of relative inter-locus
toxicity (Figure S2A).
Inter-locus polyQ toxicity correlates with repeat
expandability
We hypothesised that the rate at which somatic expandability
delivers polyQ proteins to their cytotoxic state would be a critical
factor in expanded polyQ-disease pathogenesis, and contributes
towards the observed inter-locus differences in polyQ toxicity.
Thus, we predicted that inter-locus polyQ-toxicity would be
positively correlated with locus expandability; the more toxic
polyQ loci would be those with the highest expandability. Taking
into account the effect of progenitor allele length, we previously
quantified observed differences of intergenerational variability
between expanded CAGNCTG repeat loci; calculating the relative
expandability of each locus using pedigree data gleaned from the
literature (Table 1) [31]. Employing these values of sex-averaged
expandability we found that inter-locus polyQ toxicity and locus
expandability were significantly correlated using a rank order test
(one-tailed Spearman’s rank; rho=0.75; P=0.03; N=7)
(Figure 1B). Similarly significant correlations were obtained when
an age-at-onset of 30 (one-tailed Spearman’s rank; rho=0.75;
P=0.03; N=7), 40 (one-tailed Spearman’s rank; rho=0.82;
P=0.02; N=7) or 50 (one-tailed Spearman’s rank; rho=0.82;
P=0.02; N=7) years was used to determine inter-locus polyQ
toxicity, suggesting that the inter-locus polyQ toxicity values as
determined at 32 years age-at-onset are broadly representative of
the relationship between the variables throughout the dataset as a
Figure 1. Repeat expandability correlates with inter-locus
polyQ toxicity. (A) The graph shows the exponential decay regression
lines fitted to the age-at-onset and inherited repeat length distributions
in the polyQ disorders (Huntington disease (HD)(dashed line), spinal
and bulbar muscular atrophy, X-linked (SMAX1), dentatorubral-pallido-
luysian atrophy (DRPLA), Machado-Joseph disease (MJD), spinocerebel-
lar ataxia 1 (SCA1), 2 (SCA2) and 7 (SCA7)). The inter-locus polyQ
toxicities were derived from the parameters of the regression line of
each disorder for the modal age-at-onset of 32 years (dashed lines). (B)
Plot of ranked expandability and ranked inter-locus polyQ toxicity at the
modal age-at-onset (32 years) with the regression line (one-tailed
Spearman’s rank; rho=0.75; P=0.03; N=7).
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locus polyQ toxicity and locus expandability (one-tailed Spear-
man’s rank; rho=0.75; P=0.03; N=7) was obtained when using
inter-locus toxicity values derived from a linear model of the
relationship between repeat length and age-at-onset (Figure S2B).
As detailed quantitative data on somatic instability are not
available for most of the polyQ disease loci, we have used our
previously derived measure of the relative expandability of the
repeat tract based on intergenerational transmissions [31].
Nonetheless, expanded CAGNCTG repeat transgenic mouse
models have revealed that mouse lines showing the greatest
intergenerational expandability also exhibit higher levels of
somatic expandability (e.g. [25,26,28,29]) suggesting that the two
measures are comparable. The limited human data that are
available also support a similar relationship. Examining data from
a published study of somatic expandability in post-mortem brain
tissue of SCA1 and MJD patients [55], we found that the repeat-
length normalised levels of somatic expandability in SCA1 were
approximately double the levels found in MJD in both cerebral
cortex (NMJD=11; NSCA1=7; Mann-Whitney U=0; P,0.0001)
and cerebral white matter (NMJD=9; N SCA1=6; Mann-Whitney
U=0; P,0.001); similar to the relative levels of germ line
expandability observed in these disorders (Figure 2A and Table
S1) [31]. Similarly, meta-analysis of published studies of somatic
expandability in buccal cells of HD [8] and SCA7 [47] patients,
revealed that the repeat-length normalised levels of somatic
expandability in SCA7 were significantly greater than those in
HD (NHD=12; NSCA7=1; T-test=29.58; P,0.0001). Again, the
levels of somatic expandability in HD and SCA7 were comparable
to the levels of germ line expandability observed in these disorders
(Figure 2B and Table S2) [31], suggesting that relative
intergenerational expandability is an accurate proxy of relative
somatic expandability.
Refining the association between CTGNCAG expandability
and flanking genomic DNA GC content
We previously described a significant positive correlation
between repeat expandability and the GC content of genomic
DNA flanking sequences and postulated that flanking GC content
directly modifies repeat stability [31]. When we first conducted
this analysis the human genome sequencing project was unfinished
and many flanking sequences were absent or incomplete. Here,
employing the latest assembly of the human genome (NCBI 36),
we characterised this relationship in finer detail and to a greater
distance from each locus. Employing the seven polyQ loci a
significant rank correlation between sex-averaged germ line
expandability and flanking genomic DNA GC content was found
up to a distance of 1,000 bp from the repeat when the combined
flanking sequences of the loci were analysed (Table 2). Statistically
significant correlations were also obtained when the 59 and 39
flanking sequences were analysed independently. The absence of
any significant association at distances from 1 kb to 100 kb
suggests that the observed correlations proximal to the repeats are
not a simple function of the wider chromosomal GC content
surrounding each locus (Figure 3A).
In order to further describe the area of significant association
flanking the loci, we determined a continuous GC content profile
Table 1. Inter-locus polyQ toxicity and expandability of the dynamic DNA polyQ loci.
disorder gene r
a inter-locus polyQ toxicity
b (95% C.I.) rank toxicity expandability
c rank expandability
MJD ATXN3 0.52 75.4 (75.2–76.4) 1 0.05 2
DRPLA ATN1 0.21 66.1 (64.8 - NC) 2 0.11 4
SMAX1 AR 0.39 53.3 (52.3–57.1) 3 0.03 1
HD HTT 0.40 52.2 (51.2–52.7) 4 0.14 5
SCA1 ATXN1 0.63 51.7 (51.2–52.5) 5 0.08 3
SCA7 ATXN7 0.39 48.8 (47.8–50.0) 6 0.72 6
SCA2 ATXN2 0.41 40.8 (40.5–41.9) 7 0.83 7
athe coefficient of correlation (r) of age-at-onset versus repeat length was obtained by fitting an exponential decay model to each dataset (see Figure 1 & Figure S1). All
correlations were highly significant (P,0.001).
brepeat length corresponding to an age at onset of 32 years.
csex-averaged intergenerational expandability of each disorder as previously described [31].
CI; Confidence Interval.
doi:10.1371/journal.pone.0028260.t001
Figure 2. Intergenerational instability is predictive of somatic
instability. (A) Repeat-length normalised levels of somatic mosaicism
in the brains of SCA1 and MJD patients is similar to the levels of germ
line instability observed in these disorders. Data were obtained from
meta-analysis of a published study of somatic mosaicism in the cerebral
cortex (NMJD=11, NSCA1=7) and white matter (NMJD=9, N SCA1=6) of
SCA1 and MJD individuals (Table S1) (Maciel et al, 1997). (B) Repeat-
length normalised levels of somatic mosaicism in buccal cells of HD and
SCA7 patients is similar to the levels of germ line instability observed in
these disorders. Data were obtained from meta-analysis of published
studies of somatic mosaicism in the buccal cells of HD (N=12) [8] and
SCA7 (N=1) [34] individuals (Table S2).
doi:10.1371/journal.pone.0028260.g002
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from the repeat using a sliding window of 100 bp and step size of
10 bp. Subsequently, the rank correlation of GC content with the
expandability of all loci was determined along the flanking
sequences at each 10 bp interval. These data confirmed that the
region of significant correlation was restricted to ,61 kb.
Interestingly, a substantial difference in the correlation profile of
the 59 and 39 sequences immediately adjacent to the loci was
evident. The 59 sequence shows an almost continuous significant
correlation (N=7; P,0.05) from a distance of 140 bp to 850 bp
from the loci, whereas a more punctuated profile was found 39 of
the repeat array (Figure 3B).
Inter-locus polyQ toxicity correlates with flanking
genomic DNA GC content
If repeat stability is indeed a major modifier of inter-locus polyQ
toxicity, and flanking genomic DNA GC content governs repeat
stability, a strong association between inter-locus polyQ toxicity
and flanking genomic DNA GC content would be expected.
Applying the same methodology, we analysed the association of
flanking genomic DNA GC content with inter-locus polyQ
toxicity. As we possess reliable quantitative data for both GC
content and inter-locus polyQ toxicity a product-moment
correlation (Pearson, r) was performed. A statistically significant
correlation between inter-locus polyQ toxicity and flanking
genomic DNA GC content was observed from 100 bp (Pearson’s
r=20.87, P=0.015) (Figure 4) to approximately 400 bp flanking
the repeat tract (Figure 5A). A similar highly significant association
with flanking genomic DNA GC content was observed both 59 and
39 of the CAG repeat loci (Figure 5A).
Inter-locus polyQ toxicity does not correlate with the GC
content of the mRNA or location within the gene
We considered it possible that the observed CAG repeat
genomic DNA flanking sequence GC content correlation with
inter-locus polyQ toxicity could reflect effects mediated at the level
of the mRNA. Employing manually curated RefSeq mRNA
sequences for each gene, we investigated the association between
inter-locus polyQ toxicity and mRNA GC content. No significant
correlation between inter-locus polyQ toxicity and total mRNA
GC content was found (r=20.28; P=0.58; N=7). Employing the
sliding window approach as before, a significant correlation
between flanking mRNA sequence and GC content was only
found immediately proximal (,100 bp) to the repeat tract and
dropped rapidly thereafter (Figure 5C). This small region of
significant correlation corresponds closely to the region of
sequence defined by the 59 and 39 boundaries of the repeat-
containing exons in each gene and does not extend into the
sequence coded for by adjacent exons (Figure 5B) suggesting that
the correlation between flanking genomic DNA GC content and
inter-locus polyQ toxicity does not reflect effects mediated at the
level of the mRNA. Additionally, inter-locus polyQ toxicity did not
correlate significantly with the distance of the repeat tract from
either the transcription start site (Spearman’s rank correlation;
N=7,rho=0.43, P=0.3) or translation start site (Spearman’s rank
correlation; N=7, rho=0.5, P=0.22).
Inter-locus polyQ toxicity does not correlate with
flanking protein sequence properties
Although no correlation was observed with the GC content of
the mRNA, we considered it possible that the observed correlation
between CAG repeat DNA flanking GC content and inter-locus
polyQ toxicity could reflect the GC content of codons encoding
amino acids with polyQ toxicity mediating properties. Protein
properties were quantified using published, experimentally and
empirically derived scales of protein physiochemical characteristics
(Table S3). Employing these scales of predicted amino acid
composition, flexibility, hydrophobicity, and polarity, no correla-
tion with inter-locus polyQ toxicity was identified (Figure S3).
Similarly, no correlation between predicted secondary structural
features flanking the polyQ tract (alpha helices, beta sheets, beta
turns or coils) and inter-locus polyQ toxicity was found (Figure S4).
Interestingly, several secondary structure prediction algorithms
[36,56,57,58] failed to identify any regions of conserved structure
in the sequences flanking the polyQ repeat in each protein (data
not shown) suggesting polyQ toxicity is not dependent on a
particular local structural context. Finally, inter-locus toxicity does
not correlate with the GC content of the 1st and 2nd codon
positions (which will correlate well with amino acid identity)
flanking the repeat, but does correlate with the 3rd codon GC
Table 2. Correlation of flanking genomic DNA GC content with repeat expandability of the polyQ loci.
59 flanking
sequence
39 flanking
sequence combined flanking sequence
distance from repeat rho
a P
b rho P rho P
100,000 bp 0.429 0.337 0.357 0.432 0.357 0.337
50,000 bp 0.429 0.337 0.214 0.645 0.214 0.645
10,000 bp 0.536 0.215 0.393 0.383 0.321 0.482
5,000 bp 0.500 0.253 0.214 0.645 0.214 0.645
2,500 bp 0.536 0.215 0.107 0.819 0.357 0.432
1,000 bp 0.821 0.023* 0.321 0.482 0.929 0.003*
750 bp 0.929 0.003* 0.750 0.052* 0.929 0.003*
500 bp 0.929 0.003* 0.847 0.016* 0.929 0.003*
250 bp 0.929 0.003* 0.786 0.036* 0.786 0.036*
100 bp 0.649 0.115 0.821 0.023* 0.786 0.036*
aSpearman’s rank coefficient of correlation.
bP-value of Spearman’s rank coefficient of correlation.
*statistically significant at P,0.05.
doi:10.1371/journal.pone.0028260.t002
DNA Repeat Expandability and PolyQ Toxicity
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28260content (which will not correlate well with amino acid identity),
but only for the region encompassed by the immediate flanking
exon (Figure S5).
Inter-locus polyQ toxicity does not correlate with
transcript levels
The polyQ expansions are located in various positions within
each associated gene, often very distant from the promoter. In
addition, the correlation with GC content extends only a short
distance from the repeat. Nonetheless, given the known association
between GC content and expression levels, it is possible that the
correlation with GC content reflects an effect mediated by gene
expression levels. Thus, we tested if steady state transcript levels
correlated with either the polyQ toxicity or the GC content
flanking the repeat. To investigate the relationship between inter-
locus polyQ toxicity and inter-locus polyQ gene expression levels,
we analysed recently published RNA-seq (next generation
sequencing of RNA) data of human brain [59]. We found no
significant correlation between inter-locus polyQ toxicity and
polyQ gene expression in either normal human whole brain
(r=0.33, P=0.47, N=7) or normal human cerebellum (r=0.37,
P=0.41, N=7), (Figure 6A). Similarly, no significant correlation
between flanking sequence GC content and expression was
observed (Figure 6B).
Discussion
Although the inverse relationship between age-at-onset and
repeat length is broadly similar in the dynamic DNA polyQ
disorders, the inherited number of repeats required to cause a
given age-at-onset varies dramatically between disorders (Figure 1)
[2]. Notably, the SCA2 polyQ expansion is almost twice as toxic as
the MJD expansion and there is virtually no overlap in the repeat
length distributions observed in the patient populations. Under-
standing the basis of these dramatic contextual differences could
be important in the development of therapies. For instance, if the
effect of the protective environment of the MJD repeat could be
replicated in SCA2, then individuals with SCA2 alleles less than 60
repeats (.99% of patients), might never develop symptoms. It has
been widely assumed that this inter-locus polyQ toxicity difference
is due to protein context mediated effects on polyQ tract
cytotoxicity [34,35,36,37,38]. Indeed, numerous studies have
shown that protein context can be a major modifier of polyQ
tract toxicity (e.g. [35,39,40,41,42,43,44,45]). However, until now,
no rationalisation of how protein context determines the
considerable observed inter-locus polyQ toxicity has been
described. We hypothesised that the rate at which somatic
expansion delivers a polyQ protein to its cytotoxic state would
be a critical factor in expanded polyQ-disease pathogenesis, and
could also contribute toward the observed inter-locus differences
in polyQ toxicity. Employing age-at-onset data for seven of the
polyQ disorders we quantified the inter-locus polyQ toxicity
differences and found that the inter-locus polyQ toxicity is indeed
significantly correlated with the underlying expandability of the
CAG repeat tract. Moreover, we showed that the flanking GC
Figure 4. Inter-locus polyQ toxicity correlates with genomic
DNA flanking sequence GC content. The graph shows the
regression analysis between inter-locus polyQ toxicity and the GC
content of the genomic DNA flanking sequences at a distance of
100 bp (r=20.87; P=0.01; N=7).
doi:10.1371/journal.pone.0028260.g004
Figure 3. Repeat expandability correlates with flanking
genomic DNA sequence GC content. (A) polyQ-encoding CAG-
repeat expandability correlates with proximal, but not distal flanking
genomic DNA sequence GC content. Distance from the repeat (red
vertical line) is plotted on a log scale against Spearman’s coefficient of
correlation (rho) with expandability [31]. The dashed line shows the
threshold for statistical significance (P,0.05; two-tailed). (B) The graph
shows the coefficient of correlation of flanking genomic DNA GC
content of the seven dynamic DNA CAG polyQ-encoding loci with
repeat expandability. Spearman’s rank coefficient of correlation (rho)
was calculated to a distance of 2,000 bp both 59 and 39 of each repeat
using a sliding window of 100 bp and step size of 10 bp. The dashed
line shows the threshold for statistical significance (P,0.05; two-tailed).
and The position of the CAGNCTG repeat is represented by the vertical
red bar.
doi:10.1371/journal.pone.0028260.g003
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However, as GC content and repeat expandability are correlated,
it is possible that expandability and polyQ toxicity are both
dependent variables of GC content and are not linked in a direct
cause and effect pathway. Thus, we sought to explore the
alternative explanations for this observation. Importantly, we
found that inter-locus polyQ toxicity is not correlated with the GC
content of the mRNA, the properties of the amino acid sequence,
or with the position of the repeat tract within the gene or protein.
These data appear to preclude the theory that the observed
correlation between GC content and inter-locus polyQ toxicity is
mediated by the immediate flanking amino acid sequence of the
polyQ tract. Of course, these results do not preclude a role for
broader protein context effects in mediating inter-locus polyQ
toxicity, but suggest that such effects are more likely to be
mediated by larger more complex protein domains whose
signature is not reflected in the flanking sequence of the genomic
DNA. This interpretation is consistent with the mounting evidence
indicating an important role for gain of wild-type function in the
polyQ disorders [45]. Given the known association between GC
content and promoter activity, we also considered it possible that
the correlation between GC content and inter-locus polyQ toxicity
might be mediated by gene expression levels: high expression
levels of a smaller polyQ expansion might be as toxic as lower
expression of a larger expansion. To test this hypothesis, we used
recently derived RNA deep sequencing data to test the correlation
between inter-locus polyQ toxicity and the relative steady state
transcript levels in human brain and cerebellum. These analyses
showed that neither polyQ toxicity or the GC content of the repeat
flanking DNA were correlated with steady state transcript levels.
Again, these data do not preclude a role for expression levels in
mediating some aspects of inter-locus polyQ toxicity, but indicate
that transcription levels are not the basis of the observed
correlation of GC content with inter-locus polyQ toxicity. Thus,
the most logical explanation of the data is that the significant
correlation between flanking DNA GC content and inter-locus
polyQ toxicity is a consequence of flanking GC content effects on
DNA repeat stability i.e. that the age-at-onset of an individual with
a polyQ disorder is a function of the inherited allele length coupled
with the rate at which it expands somatically, and that the somatic
expansion rate is mediated by the GC content of the flanking
DNA.
We previously detailed a significant association between
flanking GC content and locus expandability [31]. Here, analyzing
this relationship in finer detail and at greater distances from each
locus, we found a significant positive correlation between proximal
flanking GC content and repeat instability for the polyQ-encoding
CAG. The data presented here confirm that the effect is local,
limited to within 61 kb of the repeat tract, excluding an effect
mediated by high order isochore domains. Flanking GC content
may affect repeat stability by modifying the formation or stability
of the presumptive slipped strand DNA intermediates [60] or the
DNA-RNA hybrid R-loops that have been implicated in
generating them [61]. Alternatively, the GC content of the
flanking DNA may modify the downstream processing of aberrant
structures by the DNA repair machinery either directly through its
effect on the biophysical properties of DNA or through CpG
methylation effects on transcription and/or chromatin dynamics
such as CTCF-binding [30]. The effect of GC content on repeat
expandability could be directly tested in mutant mice in which the
flanking DNA sequence GC content is altered, without altering the
amino acid sequence in the mature protein.
Mutant polyQ-encoding CAG tracts also cause the atypical
disorders SCA6 and SCA17. However, neither can be classified as
a dynamic mutation since both loci are genetically relatively stable.
Even ‘expanded’ SCA6 alleles are relatively small (typically 20–30
repeats), and there is some debate as to whether SCA6 represents a
true polyQ repeat disorder. Although the carboxy terminus can
Figure 5. Inter-locus polyQ toxicity correlates with the flanking
genomic DNA sequence GC content, but does not extend
beyond the repeat containing exon in the mRNA sequence. (A)
Inter-locus polyQ toxicity correlates with the flanking genomic DNA
sequence GC content. The graph shows the coefficient of correlation (r)
for the relationship between inter-locus polyQ loci toxicity and flanking
genomic DNA sequence GC content. GC content was sampled using a
sliding window of 100 bp and a step size of 10 bp. The threshold for
statistical significance (dashed lines) and the position of the CAGNCTG
repeat (red vertical bar) are also shown. Note that the region of
statistically significant correlation extends for ,400 bp either side of
the repeat tract (as indicated by the vertical dotted lines). (B) Gene
structure of the seven polyQ containing genes. All diagrams are to
scale. Exons (white box), introns (grey box), intergenic regions
(horizontal black bar), and repeat tract (vertical black bar) are shown.
(C) Inter-locus polyQ toxicity only correlates with flanking mRNA
sequence GC content to the 59 and 39 ends of their host exons. The
graph shows the coefficient of correlation (r) for the relationship
between inter-locus polyQ toxicity and flanking mRNA sequence GC
content determined as in (A). Note that the region of statistically
significant correlation extends for only ,100 bp either side of the
repeat tract (as indicated by the vertical dashed lines) corresponding to
the length of mRNA sequence encoded by the repeat containing exons
and not extending into flanking exons.
doi:10.1371/journal.pone.0028260.g005
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neurochemical profile from SCA1 and SCA2 [63] and truncating
mutations in the same SCA6 associated CACNA1A calcium
channel gene cause the highly overlapping episodic ataxia type
2A phenotype [64]. Although expanded CAG repeat SCA17
alleles are relatively long (typically 50–60 repeats), they are nearly
always interrupted by stabilising CAA codons [65]. Nonetheless,
very rare cases of unstable pure SCA17 repeat tracts have been
reported [66,67,68,69]. Although the data for pure SCA17 repeat
transmissions are too limited (N=9) for inclusion in the main
analyses presented in this study, we decided to test whether the
relationship between expandability, inter-locus polyQ toxicity and
flanking DNA GC content of unstable SCA17 alleles fitted with
our model of somatic mosaicism mediated inter-locus polyQ
toxicity. SCA17 data was obtained by meta-analysis of published
cases of unstable SCA17 alleles (Table S4). Interestingly, inclusion
of data from unstable SCA17 loci resulted in a more significant
correlation between expandability and inter-locus polyQ toxicity
(one-tailed Spearman’s rho=0.74; N=8;P=0.02) (Figure S6A and
S6B). Moreover, the highly significant association between inter-
locus polyQ toxicity and flanking genomic DNA GC content is
maintained upon inclusion of the SCA17 locus (Figure S6C).
The data we have presented here further support a role for
somatic expansion in the dynamic DNA disorders. The hypothesis
that somatic expansion of repeats contributes towards age-at-onset
of symptoms and disease progression is further supported by a
number of observations in patients. For instance, individuals with
expanded yet stable SCA1 alleles exhibit significantly delayed
onset of symptoms [70,71] or remain asymptomatic [72]. These
individuals contain histidine-encoding CAT interruptions in the
expanded CAG repeat. SCA1 alleles containing interruptions tend
not to expand, whereas loss of repeat interruptions is associated
with repeat expansion [73]. However, it should also be noted that
the presence of histidines with the polyQ tract can also alter
aggregation dynamics [74]. Similarly, CAA interrupted CAG
expansions in ATXN2 do not induce SCA2, but instead produce a
Parkinsonian phenotype, despite the fact that both the pure and
interrupted repeat tracts encode pure polyQ [75]. Likewise, a large
group of HD patients from Crete with expanded, but for as yet
unknown reasons stable HD alleles, had a median age-at-onset
15–20 years later than expected [76]. Significantly, the CAG
repeat tract in these patients is also uninterrupted, coding for a
pure polyQ tract [77], further implicating repeat instability, not
polyQ toxicity, as the major modifier of disease progression. Most
convincingly, a recent study of somatic instability in the cortex of
HD individuals with expanded repeat tracts of similar length
found that somatic instability was a significant predictor of age at
onset [78]. The dependence of disease onset and progression on
CAG repeat expandability could be readily tested in transgenic
mice carrying either a somatically unstable pure CAG repeat tract
or a stable CAA/CAG repeat tract, both of which code for a pure
polyQ tract in the mature protein. It has already been
demonstrated that a genetically stable mixed CAA/CAG
transgene can illicit an HD like phenotype, suggesting that
somatic expansion is not essential to mediate pathology [79].
However, it needs to be considered that the multicopy transgene
used in this study was ,three fold overexpressed and contained 97
glutamine repeats, more than twice the size of the typical adult
onset HD allele (,45 repeats [2]). Balancing the size of the repeat
inserted with the limited lifespan of the mouse and the consequent
relatively limited window for somatic expansion may prove
problematic. It may thus be necessary to generate a matched
allelic series of knock-in mice with different repeat lengths to
investigate the relative importance of somatic instability.
Our model of expansion-mediated disease pathogenesis is
further supported by a recent computational study which
predicted that repeat expansion in somatic tissue determines both
age-at-onset and the rate of disease progression [53]. Employing
mathematical modeling and computer simulations, it was shown
that the more rapid disease progression observed in juvenile cases
and the similar age-at-onset, but more rapid disease progression
observed in individuals homozygous for polyQ expansions could
be accurately represented by a somatic-expansion model, but not
by a cumulative polyQ toxicity model [53]. This mathematical
model would directly predict that the age of onset relationships for
each disease would be shifted as we have revealed by locus-specific
effects on mutational dynamics.
These data further support the concept that somatic expansion
makes a substantial contribution to disease progression. As such,
treatments that resulted in a suppression of repeat expansion
Figure 6. Steady-state transcript levels in human brain do not correlate with inter-locus toxicity or flanking DNA GC content.
(A) Correlation (Pearson, r) between inter-locus toxicity and polyQ gene steady-state transcript levels in whole brain (r=0.33, P=0.47; yellow
diamond) or cerebellum (r=0.37, P=0.31; red diamond). (B) Correlation (Pearson, r) between 500 bp flanking DNA GC (%) content and polyQ gene
steady-state transcript levels in whole brain (r=0.07, P=0.89) or cerebellum (r=0.34, P=0.46). Similarly, no significant correlation was observed
between polyQ gene steady-state transcript levels and 100 bp flanking DNA GC (%) content (brain, r=20.07, P=0.89; cerebellum, r=20.09, P=0.85)
or 2000 bp flanking DNA GC (%) content (brain, r=0.37, P=0.41; cerebellum, r=0.34, P=0.46). Steady-state transcript levels values are averages of
values from multiple independent samples of normal human whole brain (N=2, yellow diamond) and cerebellum (N=6, red diamond). The least
squares linear regression lines are shown for whole brain (solid) and cerebellum (dashed). Steady-state transcript levels were calculated as ‘reads per
kilobase of exon model per million mapped reads’ (RPKM) [59]. RPKM values are shown in log10 scale for.
doi:10.1371/journal.pone.0028260.g006
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critical role played by Msh2 and Msh3 in the expansion pathway
[14,15], these proteins present themselves as potential therapeutic
targets. Indeed, the introduction of an Msh2 null allele in a knock-
in HD mouse model resulted in a 5-month delay in the
appearance of aggregates [80]. Although suppression of Msh2
would be expected to lead to a cancer predisposition phenotype
[81], Msh3 knockouts are not cancer prone [82].
We have revealed a significant association between inter-locus
polyQ toxicity and both repeat expandability and the GC
content of the flanking DNA. These data provide the first
quantitative insights into how to rationalise the observed
dramatic differences in inter-locus polyQ toxicity. Of course,
these data do not preclude a role for protein context in also
contributing toward inter-locus polyQ toxicity and, given the
dramatic effects on polyQ toxicity observed in vitro, it would be a
major surprise if they did not. Likewise, gene expression levels
and the tissue-specificity of gene expression patterns would also
be expected to contribute. Nonetheless, the coefficient of
correlation between GC content and inter-locus polyQ toxicity,
r=20.76, suggests that flanking GC content accounts for ,57%
of the considerable inter-locus variation in polyQ toxicity.
Assuming that a sizeable proportion of this effect is mediated via
effects on repeat stability, then these data provide the first
quantitative insights into how effective therapies that stabilised
the repeat tract might be.
Methods
All genomic DNA analyses used the NCBI 36 (November 2005)
assembly of the human genome, obtained from the Ensembl web
server (url: http://www.ensembl.org/index.html). The accession
numbers of the mRNA sequences employed for each disorder
were; NM_001007026 (ATN1), NM_000332 (ATXN1),
NM_002973 (ATXN2), NM_000333 (ATXN7), NM_004993
(ATXN3), NM_000044 (AR) and NM_002111 (HTT). The
accession numbers of the protein sequences employed were;
NP_001007027 (ATN1), NP_000323.2 (ATXN1), NP_002964.2
(ATXN2), NP_000324 (ATXN7), NP_004984 (ATXN3),
NP_000035 (AR) and NP_002102 (HTT). Repeat length versus
age-at-onset data for each locus was previously collated from
published studies [2]. Protein scales were obtained from the
ExPASy proteomics server (url: http://www.expasy.ch/). All GC
content analyses were performed with custom written software
implemented in the Perl programming language. STRIDE, DSSP,
and STR secondary structure predictions were performed via the
SAM server (url: http://www.soe.ucsc.edu/research/compbio/
sam.html). SPSS (version 13) and GraphPad PrismH (version 5)
were used for statistical analyses.
Supporting Information
Figure S1 Detailed illustration of exponential decay
model of the relationship between age at onset and
repeat number. 95% confidence bands (red lines) of regression
line describing the relationship between age-at-onset and repeat
number for each disorder. Confidence limits of regression line
were determined using GraphPad PrismH (version 5).
(TIF)
Figure S2 The correlation between expandability and
toxicity is maintained when using a linear function to
describe the relationship between age-at-onset and
repeat length. (A) The graph shows the linear regression lines
fitted to the age-at-onset and inherited repeat length distributions
in the seven polyQ disorders. The inter-locus polyQ toxicities were
derived from the parameters of the regression line of each disorder
for the modal age-at-onset of 32 years (dashed lines). (B) Plot of
ranked expandability and ranked inter-locus polyQ toxicity at the
modal age-at-onset (32 years) with the regression line. (one-tailed
Spearman’s rank; rho=0.75; P=0.03; N=7).
(TIF)
Figure S3 Correlation of flanking primary amino acid
sequence properties with inter-locus polyQ toxicity.
Using a window size of 21 amino acids and a step size of one,
locus toxicity was correlated (Spearman’s rank) with various
physiochemical and compositional characteristics of the primary
protein sequence at every amino-acid position flanking the polyQ
repeat. Repeat size was normalised to 21 glutamines. The dashed
lines represent the threshold for statistical significance (P,0.05).
As the 39 sequence of ATXN3 extends just 83 amino acids away
from the repeat, all correlations beyond this point involve the
remaining six sequences with a correspondingly higher 5%
significance threshold. Amino-acid properties were derived from
the sources indicated in Table S3. Similar profiles were obtained
using sliding window sizes of 15 and 11 amino-acids (data not
shown).
(TIF)
Figure S4 Correlation of predicted flanking secondary
protein structure with inter-locus polyQ toxicity. Using a
window size of four amino-acids and a step size of one, inter-locus
polyQ toxicity was correlated (Spearman’s rank) with the
predicted secondary structure as determined from scales of
secondary structure formation potential at every amino acid
position flanking the polyQ repeat. Repeat size was normalised to
21 glutamines. The dashed lines represent the threshold for
statistical significance (P,0.05). As the 39 sequence of ATXN3
extends just 83 amino acids away from the repeat, all correlations
beyond this point involve the remaining six sequences with a
correspondingly higher 5% significance threshold. Amino-acid
properties were derived from the sources indicated in Table S3.
Similar profiles were obtained using sliding window sizes of 15 and
11 amino-acids (data not shown).
(TIF)
Figure S5 Inter-locus polyQ toxicity does not correlate
with 1st and 2nd base GC content. Inter-locus polyQ toxicity
does not correlate with 1st and 2nd base GC content, but does
correlate with the 3rd base GC content. GC content was sampled
using a sliding window of 30 bp (10 codons) and a step size of 3 bp
(1 codon). The threshold for statistical significance (dashed lines) is
also shown. Only sequences 39 of the CAG repeat tract were
analysed as insufficient sequence is present 59 of the repeat due to
proximity of the repeat tract to the transcription start site at many
loci (e.g. HTT, ATXN2).
(TIF)
Figure S6 Inclusion of unstable SCA17 alleles strength-
ens correlation between inter-locus toxicity and expand-
ability. (A) The graph shows the exponential decay regression
lines fitted to the age-at-onset and inherited repeat length
distributions in the eight polyQ disorders including SCA17. The
inter-locus polyQ toxicities were derived from the parameters of
the regression line of each disorder for the modal age-at-onset of
30.5 years (dashed lines). (B) Plot of ranked expandability and
ranked inter-locus polyQ toxicity at the modal age-at-onset (30.5
years) with the regression line (one-tailed Spearman’s rank;
rho=0.74; P=0.02; N=8). (C) The graph shows the regression
analysis between inter-locus polyQ toxicity and the GC content of
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(r=20.77; P=0.01; N=8).
(TIF)
Table S1 A. Age-at-death and somatic expandability in
MJD patients. B. Age-at-death and somatic expandabil-
ity in SCA1 patients. C. Levels of somatic expandability
are greater in SCA1 than MJD.
(DOC)
Table S2 A. Somatic expandability in buccal cells of HD
patients
1. B. Somatic expandability
* in buccal cells of
SCA7 patients
1. C. Levels of somatic expandability are
greater in SCA7 than HD.
(DOC)
Table S3 Inter-locus polyQ toxicity and expandability
of the dynamic DNA polyQ loci.
(DOC)
Table S4 Age-at-onset and expandability of unstable
SCA17 alleles.
(DOC)
Acknowledgments
We would like to thank Peggy F. Shelbourne, Richard H. Wilson, Mark E.
S. Bailey and colleagues at the University of Glasgow for helpful discussions
during the course of this work and James Gusella and Marcy MacDonald
at the Massachusetts General Hospital for kindly providing the age-at-onset
and inherited repeat length data.
Author Contributions
Conceived and designed the experiments: CEN DGM. Performed the
experiments: CEN. Analyzed the data: CEN. Contributed reagents/
materials/analysis tools: CEN. Wrote the paper: CEN DGM. Designed the
software used in analysis: CEN.
References
1. Gomes-Pereira M, Monckton DG (2006) Chemical modifiers of unstable
expanded simple sequence repeats: what goes up, could come down. Mutat Res
598: 15–34.
2. Gusella JF, MacDonald ME (2000) Molecular genetics: unmasking polygluta-
mine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109–115.
3. Richards RI, Sutherland GR (1992) Heritable unstable DNA sequences. Nat
Genet 1: 7–9.
4. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, et al. (1991) Variation of the
CGG repeat at the fragile X site results in genetic instability: resolution of the
Sherman paradox. Cell 67: 1047–1058.
5. Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes J-P, Duros C, et al.
(1993) Myotonic dystrophy: size and sex dependent dynamics of CTG meiotic
instability, and somatic mosaicism. American Journal Of Human Genetics 52:
875–883.
6. Gouw LG, Castaneda MA, McKenna CK, Digre KB, Pulst SM, et al. (1998)
Analysis of the dynamic mutation in the SCA7 gene shows marked parental
effects on CAG repeat transmission. Hum Mol Genet 7: 525–532.
7. Ellegren H (2000) Heterogeneous mutation processes in human microsatellite
DNA sequences. Nat Genet 24: 400–402.
8. Veitch NJ, Ennis M, McAbney JP, Shelbourne PF, Monckton DG (2007)
Inherited CAG.CTG allele length is a major modifier of somatic mutation
length variability in Huntington disease. DNA Repair (Amst) 6: 789–796.
9. Wong LJ, Ashizawa T, Monckton DG, Caskey CT, Richards CS (1995) Somatic
heterogeneity of the CTG repeat in myotonic dystrophy is age and size
dependent. Am J Hum Genet 56: 114–122.
10. Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, et al. (2003) Dramatic
tissue-specific mutation length increases are an early molecular event in
Huntington disease pathogenesis. Hum Mol Genet 12: 3359–3367.
11. Ashizawa T, Dubel JR, Harati Y (1993) Somatic instability of CTG repeat in
myotonic dystrophy. Neurology 43: 2674–2678.
12. Anvret M, Ahlberg G, Grandell U, Hedberg B, Johnson K, et al. (1993) Larger
expansions of the CTG repeat in muscle compared to lymphocytes from patients
with myotonic dystrophy. Hum Mol Genet 2: 1397–1400.
13. Thornton CA, Johnson K, Moxley RT, 3rd (1994) Myotonic dystrophy patients
have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol
35: 104–107.
14. Manley K, Shirley TL, Flaherty L, Messer A (1999) Msh2 deficiency prevents in
vivo somatic instability of the CAG repeat in Huntington disease transgenic
mice. Nat Genet 23: 471–473.
15. van den Broek WJ, Nelen MR, Wansink DG, Coerwinkel MM, te Riele H, et al.
(2002) Somatic expansion behaviour of the (CTG)n repeat in myotonic
dystrophy knock-in mice is differentially affected by Msh3 and Msh6
mismatch-repair proteins. Hum Mol Genet 11: 191–198.
16. Gomes-Pereira M, Fortune MT, Ingram L, McAbney JP, Monckton DG (2004)
Pms2 is a genetic enhancer of trinucleotide CAG.CTG repeat somatic
mosaicism: implications for the mechanism of triplet repeat expansion. Hum
Mol Genet 13: 1815–1825.
17. Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, et al. (2007) OGG1
initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature
447: 447–452.
18. Dion V, Lin Y, Hubert L, Jr., Waterland RA, Wilson JH (2008) Dnmt1
deficiency promotes CAG repeat expansion in the mouse germline. Human
Molecular Genetics 17: 1306–1317.
19. Tome S, Panigrahi GB, Lopez Castel A, Foiry L, Melton DW, et al. (2011)
Maternal germline-specific effect of DNA ligase I on CTG/CAG instability.
Human molecular genetics 20: 2131–2143.
20. Hubert L, Jr., Lin Y, Dion V, Wilson JH (2011) Xpa deficiency reduces CAG
trinucleotide repeat instability in neuronal tissues in a mouse model of SCA1.
Human Molecular Genetics.
21. Lee JM, Zhang J, Su AI, Walker JR, Wiltshire T, et al. (2010) A novel approach
to investigate tissue-specific trinucleotide repeat instability. BMC Systems
Biology 4: 29.
22. Kovtun IV, McMurray CT (2001) Trinucleotide expansion in haploid germ cells
by gap repair. Nat Genet 27: 407–411.
23. Foiry L, Dong L, Savouret C, Hubert L, Riele HT, et al. (2006) Msh3 is a
limiting factor in the formation of intergenerational CTG expansions in DM1
transgenic mice. Hum Genet 119: 520–526.
24. Cleary JD, Pearson CE (2003) The contribution of cis-elements to disease-
associated repeat instability: clinical and experimental evidence. Cytogenet
Genome Res 100: 25–55.
25. Fortune MT, Vassilopoulos C, Coolbaugh MI, Siciliano MJ, Monckton DG
(2000) Dramatic, expansion-biased, age-dependent, tissue-specific somatic
mosaicism in a transgenic mouse model of triplet repeat instability. Hum Mol
Genet 9: 439–445.
26. Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, et al. (1997) Instability
of highly expanded CAG repeats in mice transgenic for the Huntington’s disease
mutation. Nat Genet 15: 197–200.
27. Monckton DG, Coolbaugh MI, Ashizawa KT, Siciliano MJ, Caskey CT (1997)
Hypermutable myotonic dystrophy CTG repeats in transgenic mice. Nat Genet
15: 193–196.
28. Seznec H, Lia-Baldini AS, Duros C, Fouquet C, Lacroix C, et al. (2000)
Transgenic mice carrying large human genomic sequences with expanded CTG
repeat mimic closely the DM CTG repeat intergenerational and somatic
instability. Hum Mol Genet 9: 1185–1194.
29. Libby RT, Monckton DG, Fu YH, Martinez RA, McAbney JP, et al. (2003)
Genomic context drives SCA7 CAG repeat instability, while expressed SCA7
cDNAs are intergenerationally and somatically stable in transgenic mice. Hum
Mol Genet 12: 41–50.
30. Libby RT, Hagerman KA, Pineda VV, Lau R, Cho DH, et al. (2008) CTCF cis-
regulates trinucleotide repeat instability in an epigenetic manner: a novel basis
for mutational hot spot determination. PLoS Genet 4: e1000257.
31. Brock GJ, Anderson NH, Monckton DG (1999) Cis-acting modifiers of
expanded CAG/CTG triplet repeat expandability: associations with flanking
GC content and proximity to CpG islands. Hum Mol Genet 8: 1061–1067.
32. Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA,
et al. (1997) Ectopically expressed CAG repeats cause intranuclear inclusions
and a progressive late onset neurological phenotype in the mouse. Cell 91:
753–763.
33. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, et al. (2000) Expanded
polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegen-
eration in Drosophila. Hum Mol Genet 9: 13–25.
34. Riley BE, Orr HT (2006) Polyglutamine neurodegenerative diseases and
regulation of transcription: assembling the puzzle. Genes Dev 20: 2183–2192.
35. de Chiara C, Menon RP, Dal Piaz F, Calder L, Pastore A (2005) Polyglutamine
is not all: the functional role of the AXH domain in the ataxin-1 protein. J Mol
Biol 354: 883–893.
36. La Spada AR, Taylor JP (2003) Polyglutamines placed into context. Neuron 38:
681–684.
37. Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion:
mechanisms and common principles. Nat Rev Genet 6: 743–755.
38. Robertson AL, Bottomley SP (2010) Towards the Treatment of Polyglutamine
Diseases: The Modulatory Role of Protein Context. Curr Med Chem.
DNA Repeat Expandability and PolyQ Toxicity
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e2826039. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking
sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad
Sci U S A 103: 11045–11050.
40. Menon RP, Pastore A (2006) Expansion of amino acid homo-sequences in
proteins: Insights into the role of amino acid homo-polymers and of the protein
context in aggregation. Cell Mol Life Sci.
41. Chai Y, Berke SS, Cohen RE, Paulson HL (2004) Poly-ubiquitin binding by the
polyglutamine disease protein ataxin-3 links its normal function to protein
surveillance pathways. J Biol Chem 279: 3605–3611.
42. Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, et al. (2006) CHIP
protects from the neurotoxicity of expanded and wild-type ataxin-1 and
promotes their ubiquitination and degradation. J Biol Chem.
43. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, et al. (2003) Serine
776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic
mice. Neuron 38: 375–387.
44. Duvick L, Barnes J, Ebner B, Agrawal S, Andresen M, et al. (2010) SCA1-like
disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid
replacement at residue 776. Neuron 67: 929–935.
45. Kratter IH, Finkbeiner S (2010) PolyQ disease: too many Qs, too much
function? Neuron 67: 897–899.
46. Leeflang EP, Zhang L, Tavare S, Hubert R, Srinidhi J, et al. (1995) Single sperm
analysis of the trinucleotide repeats in the Huntington’s disease gene:
quantification of the mutation frequency spectrum. Hum Mol Genet 4:
1519–1526.
47. Monckton DG, Cayuela ML, Gould FK, Brock GJ, Silva R, et al. (1999) Very
large (CAG)(n) DNA repeat expansions in the sperm of two spinocerebellar
ataxia type 7 males. Hum Mol Genet 8: 2473–2478.
48. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM (1997) The
prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2
trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.
Am J Hum Genet 60: 842–850.
49. Benton CS, de Silva R, Rutledge SL, Bohlega S, Ashizawa T, et al. (1998)
Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the
infantile phenotype. Neurology 51: 1081–1086.
50. Cummings CJ, Zoghbi HY (2000) Fourteen and counting: unraveling
trinucleotide repeat diseases. Hum Mol Genet 9: 909–916.
51. Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O (2006) Juvenile
Huntington’s disease: does a dosage-effect pathogenic mechanism differ from the
classical adult disease? Mech Ageing Dev 127: 208–212.
52. David G, Durr A, Stevanin G, Cancel G, Abbas N, et al. (1998) Molecular and
clinical correlations in autosomal dominant cerebellar ataxia with progressive
macular dystrophy (SCA7). Hum Mol Genet 7: 165–170.
53. Kaplan S, Itzkovitz S, Shapiro E (2007) A Universal Mechanism Ties Genotype
to Phenotype in Trinucleotide Diseases. PLoS Comput Biol 3: e235.
54. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, et al. (2004)
Venezuelan kindreds reveal that genetic and environmental factors modulate
Huntington’s disease age of onset. Proc Natl Acad Sci U S A 101: 3498–3503.
55. Maciel P, Lopes-Cendes I, Kish S, Sequeiros J, Rouleau GA (1997) Mosaicism of
the CAG repeat in CNS tissue in relation to age at death in spinocerebellar
ataxia type 1 and Machado-Joseph disease patients. Am J Hum Genet 60:
993–996.
56. Frishman D, Argos P (1995) Knowledge-based protein secondary structure
assignment. Proteins 23: 566–579.
57. Heinig M, Frishman D (2004) STRIDE: a web server for secondary structure
assignment from known atomic coordinates of proteins. Nucleic Acids Res 32:
W500–502.
58. Karchin R, Cline M, Mandel-Gutfreund Y, Karplus K (2003) Hidden Markov
models that use predicted local structure for fold recognition: alphabets of
backbone geometry. Proteins 51: 504–514.
59. Ramskold D, Wang ET, Burge CB, Sandberg R (2009) An abundance of
ubiquitously expressed genes revealed by tissue transcriptome sequence data.
PLoS Comput Biol 5: e1000598.
60. Pearson CE, Sinden RR (1996) Alternative structures in duplex DNA formed
within the trinucleotide repeats of the myotonic dystrophy and fragile X loci.
Biochemistry 35: 5041–5053.
61. Lin Y, Dent SY, Wilson JH, Wells RD, Napierala M (2010) R loops stimulate
genetic instability of CTG.CAG repeats. Proceedings of the National Academy
of Sciences of the United States of America 107: 692–697.
62. Ishiguro T, Ishikawa K, Takahashi M, Obayashi M, Amino T, et al. (2010) The
carboxy-terminal fragment of alpha(1A) calcium channel preferentially aggre-
gates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells.
Acta Neuropathologica 119: 447–464.
63. Oz G, Iltis I, Hutter D, Thomas W, Bushara KO, et al. (2011) Distinct
neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple
system atrophy. Cerebellum 10: 208–217.
64. Frontali M (2001) Spinocerebellar ataxia type 6: channelopathy or glutamine
repeat disorder? Brain Res Bull 56: 227–231.
65. Tomiuk J, Bachmann L, Bauer C, Rolfs A, Schols L, et al. (2007) Repeat
expansion in spinocerebellar ataxia type 17 alleles of the TATA-box binding
protein gene: an evolutionary approach. Eur J Hum Genet 15: 81–87.
66. Rasmussen A, De Biase I, Fragoso-Benitez M, Macias-Flores MA, Yescas P, et
al. (2007) Anticipation and intergenerational repeat instability in spinocerebellar
ataxia type 17. Ann Neurol 61: 607–610.
67. Zuhlke C, Dalski A, Schwinger E, Finckh U (2005) Spinocerebellar ataxia type
17: report of a family with reduced penetrance of an unstable Gln49 TBP allele,
haplotype analysis supporting a founder effect for unstable alleles and
comparative analysis of SCA17 genotypes. BMC Med Genet 6: 27.
68. Gao R, Matsuura T, Coolbaugh M, Zuhlke C, Nakamura K, et al. (2008)
Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17.
Eur J Hum Genet 16: 215–222.
69. Maltecca F, Filla A, Castaldo I, Coppola G, Fragassi NA, et al. (2003)
Intergenerational instability and marked anticipation in SCA-17. Neurology 61:
1441–1443.
70. Matsuyama Z, Izumi Y, Kameyama M, Kawakami H, Nakamura S (1999) The
effect of CAT trinucleotide interruptions on the age at onset of spinocerebellar
ataxia type 1 (SCA1). J Med Genet 36: 546–548.
71. Quan F, Janas J, Popovich BW (1995) A novel CAG repeat configuration in the
SCA1 gene: implications for the molecular diagnostics of spinocerebellar ataxia
type 1. Hum Mol Genet 4: 2411–2413.
72. Frontali M, Novelletto A, Annesi G, Jodice C (1999) CAG repeat instability,
cryptic sequence variation and pathogeneticity: evidence from different loci.
Philos Trans R Soc Lond B Biol Sci 354: 1089–1094.
73. Chung MY, Ranum LP, Duvick LA, Servadio A, Zoghbi HY, et al. (1993)
Evidence for a mechanism predisposing to intergenerational CAG repeat
instability in spinocerebellar ataxia type I. Nat Genet 5: 254–258.
74. Jayaraman M, Kodali R, Wetzel R (2009) The impact of ataxin-1-like histidine
insertions on polyglutamine aggregation. Protein Engineering, Design and
Selection 22: 469–478.
75. Charles P, Camuzat A, Benammar N, Sellal F, Destee A, et al. (2007) Are
interrupted SCA2 CAG repeat expansions responsible for parkinsonism?
Neurology 69: 1970–1975.
76. Tzagournissakis M, Fesdjian CO, Shashidharan P, Plaitakis A (1995) Stability of
the Huntington disease (CAG)n repeat in a late onset form occuring on the
Island of Crete. Hum Mol Genet 4: 2239–2243.
77. Kartsaki E, Spanaki C, Tzagournissakis M, Petsakou A, Moschonas N, et al.
(2006) Late-onset and typical Huntington disease families from Crete have
distinct genetic origins. Int J Mol Med 17: 335–346.
78. Swami M, Hendricks AE, Gillis T, Massood T, Mysore J, et al. (2009) Somatic
expansion of the Huntington’s disease CAG repeat in the brain is associated with
an earlier age of disease onset. Hum Mol Genet 18: 3039–3047.
79. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, et al. (2008) Full-
length human mutant huntingtin with a stable polyglutamine repeat can elicit
progressive and selective neuropathogenesis in BACHD mice. The Journal of
Neuroscience 28: 6182–6195.
80. Wheeler VC, Lebel LA, Vrbanac V, Teed A, te Riele H, et al. (2003) Mismatch
repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum.
Hum Mol Genet 12: 273–281.
81. Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, et al. (1995) Msh2
deficient mice are viable and susceptible to lymphoid tumours. Nature Genetics
11: 64–70.
82. Edelmann W, Umar A, Yang K, Heyer J, Kucherlapati M, et al. (2000) The
DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor
suppression. Cancer Research 60: 803–807.
DNA Repeat Expandability and PolyQ Toxicity
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28260